Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.
Hepatic oxidation is a major drug metabolising process and is carried out by the cytochrome P-450 monooxygenase system. This system consists of a variety of isoenzymes among which the cytochromes 1A2, 2C8, 2C9/10, 2C19, 2D6, 2E1 and 3A4 are involved in the oxidative metabolism of drugs. Interindividually, large differences in capacities are found. These differences are partly due to genetic constitution (genetic polymorphism, which has been proved to exist for CYP2D6 and CYP2C19) and partly due to environmental factors, among which the administration of interfering drugs can play a major role.
Touw
D J
DJ
Department of Pharmacy, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
D000375:Aging / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology*; D004347:Drug Interactions / Q000502:physiology*; D005260:Female; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D004364:Pharmaceutical Preparations / Q000378:metabolism; D011110:Polymorphism, Genetic; D012727:Sex Characteristics
D004364:Pharmaceutical Preparations; D003577:Cytochrome P-450 Enzyme System